Atossa Therapeutics (ATOS) Q4 2024 Earnings Report

The earnings call presented a generally positive outlook with notable reductions in operating costs and promising clinical advancements for (Z)-endoxifen, particularly in metastatic breast cancer. However, the financial impact of a write-off and decreased interest income offset some of these positives.

In their recent earnings call, Atossa Therapeutics provided guidance highlighting several key metrics. Operating expenses for 2024 decreased to $27.6 million, down from $31.4 million in 2023, due to disciplined spending in R&D and G&A. R&D expenses fell by $3.2 million to $14.1 million, driven by a $2.6 million reduction in spending on (Z)-endoxifen trials. G&A expenses decreased slightly to $13.5 million, with a $1.9 million reduction in compensation costs. The company reported a net loss of $25.5 million or $0.20 per share, compared to $30.1 million or $0.24 per share in the previous year. Atossa closed the year with $71.1 million in cash and cash equivalents, providing a strong financial position to advance their lead program, (Z)-endoxifen, particularly in metastatic breast cancer settings. Additionally, a Phase I study demonstrated a clinical benefit rate of approximately 26% in patients with previous progression on multiple therapies, and a related Phase II study suggested nearly a five-month improvement in progression-free survival for certain subgroups. The company plans to focus on the U.S. FDA process for a streamlined path to market, with further guidance expected as they engage with key opinion leaders and regulatory authorities.